Review Article
Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis
Table 1
Basic details of included studies.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note: A: total effective treatment rate; B: luteinizing hormone (LH) + follicle-stimulating hormone (FSH) + estrogen (E2) levels; C: lipid index levels (triglyceride [TG], total cholesterol [TC], low-density lipoprotein-cholesterol [LDL-C], high-density lipoprotein-cholesterol [HDL-C]); D: ovarian resistance index (RI), perfusion index (PI), and peak systolic velocity (PSV); E: antral follicle count (AFC); F: anti-Müllerian hormone (AMH); G: Kupperman score; H: mean ovarian diameter (MOD) in the plane containing the longest axis of the ovary; NR: no report. In each study, all the baseline characteristics were equally distributed between the trial and control groups. |